OGI INVESTORS’ PRESENTATION |
OGI INVESTOR PRESENTATION
NASDAQ (OGI) TSX (OGI)
OGI INVESTOR PRESENTATION NASDAQ (OGI) TSX (OGI) OGI INVESTORS - - PowerPoint PPT Presentation
OGI INVESTOR PRESENTATION NASDAQ (OGI) TSX (OGI) OGI INVESTORS PRESENTATION | Cautionary Statement considered in the context of the circumstances prevailing at the time and OGI undertakes no obligation to T his document is current as of
OGI INVESTORS’ PRESENTATION |
NASDAQ (OGI) TSX (OGI)
This document is current as of August 12, 2020, except where otherwise stated. The information contained in
this presentation is provided by Organigram (“OGI” or the “Company”) for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of OGI
any contract, commitment or investment decisions in relation thereto. The information contained herein is not investment or financial product advice and is not intended to be used as the basis for making an investment
No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. This presentation is not meant to provide a complete or comprehensive analysis of OGI’s financial or business prospects. To the maximum extent permitted by law, none of OGI nor its directors, officers, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. Certain of the information in this presentation contains certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking information”). Forward-looking information, in general, can be identified by words such as “outlook”, “objective”, “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “continue”, “budget”, “schedule” or “forecast” and other similar words, or statements that certain events or conditions “may”, “could”, “would’, “might” or “will” occur. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in forward-looking information, including, among others, the Company and its subsidiaries will be able to, where applicable, cultivate cannabis pursuant to applicable law and on the currently anticipated timelines; industry competition; general economic conditions and global events including the impact, duration and magnitude of COVID-19, heightened uncertainty as a result of COVID-19; changing market and consumer patterns related to existing and new product forms and yet to be launched products; modified facility plans and production plans; timing for launch of new product forms, actions of customers, suppliers, partners, distributors, competitors or regulatory authorities; factors impacting the future market of the Canadian cannabis market and the Company’s future economic performance, OGI’s crop yields, product liability, government regulation, legislative and regulatory developments (including in relation to cannabis from Health Canada), demand for the Company’s cannabis and related products, including the Company’s Rec 2.0 products, and the sufficiency of the retail networks to supply such demand; ability to enter and participate in international market opportunities; general economic, financial market, regulatory and political conditions in which the Company operates; the ability of the Company to compete in the cannabis industry; a material decline in cannabis prices, as well as those risk factors identified in OGI’s most recent MD&A, AIF and
disclosure documents available
SEDAR at www.sedar.com and www.sec.gov/edgar.shtml under OGI’s issuer profile. The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and OGI undertakes no obligation to update forward-looking information to reflect material developments which may occur after the date this presentation was prepared or if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. The financial information in this document contains certain financial performance measures that are not defined by and do not have any standardized meaning under IFRS and are used by management to assess the financial and operational performance of the Company. These include adjusted EBITDA and adjusted EBITDA as a percentage of net revenue (adjusted EBITDA margin %). The Company believes that these non-IFRS financial measures, in addition to conventional measures prepared in accordance with IFRS, enable investors to evaluate the Company’s operating results, underlying performance and prospects in a similar manner to the Company’s
approach may differ from those used by other issuers, and accordingly, the use of these measures may not be directly comparable. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. For further information regarding these non-IFRS measures, including definitions, a quantitative reconciliation to the most directly comparable IFRS measure, see the Company’s Fiscal 2019 MD&A and the Company’s Q3 Fiscal 2020 MD&A. This presentation does not constitute an offer of shares for sale in the United States or to any person that is, or is acting for the account or benefit of, any U.S. person as defined in Regulation S under the United States Securities Act of 1933, as amended (the “Securities Act”) (“U.S. Person”), or in any other jurisdiction in which such an offer would be illegal. OGI’s shares have not been and will not be registered under the Securities Act. We seek safe harbour. This document may not be reproduced, further distributed or published in whole or in part by any other person. This document may only be disseminated or transmitted into any jurisdiction in compliance with, and subject to, applicable securities laws. Readers are required to ensure their compliance with applicable securities laws.
2
3
Medical & Adult Recreational Markets
cultivation technology
automation
4
Pre-rolls 7% & other
value segment of the adult-use recreational market
conditions
established medical cannabis producers, Canndoc Ltd. with up to 6,000kg of dried flower in a multi- year agreement
(1.0) 19.9
FY-2018 FY-2019
($M)
NET REVENUE GROSS MARGIN
before FV CHANGES to BIO ASSETS & INVENTORIES
times or 547% from 2018 on the legalization of adult-use recreational cannabis in Canada
value changes to bio assets and inventory increased 575% to 47% from 2018
margin2 of 25% as a percentage of net revenue
revenue
37.1 1.0 8.8 24.8 26.9 12.4
5
12.4 80.4
FY-2018 FY-2019
($M)
5.6 37.9 45%
47%
FY-2018 FY-2019
($M and %)
$0.07 per share (fully diluted) largely due to fair value changes to bio assets and inventory
POSITIVE ADJUSTED EBITDA2 NET INCOME (LOSS)4
footprint
state-of-the-art technology and innovation
6
1 Target production capacity once licensed and fully operational; several factors can cause actual capacity and costs to differ from estimates. See “Risk Factors” in the Company’s Q3 2020 MD&A.
~20% - revised target production capacity is now estimated at 70,000 kg/yr1 (from 89,000 kg/yr)
expected consumer demand
2020
7
being refurbished for:
Fiscal 2020, largely related to the installation of certain equipment in the edibles and extraction areas
8
1 Several factors can cause actual capacity and costs to differ from estimates. See “Risk Factors” in the Company’s Q3 2020 MD&A.
8
9
Pricing Segment Value Value Mainstream Mainstream Premium Available / Planned Formats Whole Flower, Pre-Roll, Edibles, Vape Pens Whole Flower Organic Whole Flower Whole Flower, Pre-Roll, Oil, Edibles, Vape Pens Large Whole Flower Tangible Brand Attributes Price Leader Consistent Value Offering (Strain Specific) Organically Grown in Living Soil High THC Premium Sorted Flower Robust Product Offering Top Flower Craft Cured Hand Trimmed
Note: “Buds” is interim brand name and logo and OGI is developing new permanent brand name and logo.
PRODUCTS LAUNCH TIMING VALUE in large format segment 7g & 15g Trailblazer line extensions Launched early July 2020 VALUE in large format segment Buds 28g launch in Ontario (already in Alberta and Atlantic Canada) Launched mid July 2020 NEW SKUs for our most popular strains 3-pack Pre-Rolls (3 strains) 1g & 3.5g Limelight line extension Launched June 2020 NEW CULTIVARS with Higher THC 3 new genetics- The General (Grapefruit GG4), Chemdog & limited time offer: Samurai Spy (Ninja Fruit) Launched in early Aug 2020
10 10
December 2019
February 2020
premium closed loop vaporizer system created by PAX Labs, Inc.
app-controlled vape technologies for cannabis
industrial design-patented vaporizer hardware and technology
11
high-capacity, fully-automated production line that includes advanced engineering, robotics, high-speed labeling, automated carton packing
completed in January 2020
2020, Edison Bytes, premium truffles in milk and dark chocolate available in 2 with 5mg of THC each or 1 with 10mg
segment cannabis-infused chocolate bar in late July 2020; to be available in two flavours, mocha and mint chocolate with 10 mg of THC in every 42g bar
12
ingested by adding to a liquid
salinity, pH and sweeteners as well as being shelf stable, water-compatible, and unflavoured
their choice while also offering discretion, portability and shelf life of a dry powder
13
14
Won Top Product Award in the High THC Bottled Oil Category for our medical product, Rossignol Runner-up for medical High THC Bottled Oil Banook and recognized in 7 other categories
15
Products from our Edison Cannabis Co. Brand have been chosen as the best in Canada!
TOP CBD OIL EDISON CBD TOP THC OIL EDISON SATIVA TOP THC-DOMINANT FLOWER LA STRADA TOP PRE-ROLL EL DORADO PRE-ROLL
Top Licensed Producer, #2 The Edison Cannabis Co
Mentions:
Top THC-Dominant Flower, #7 Rio Bravo Top Pre-Roll, #4 Edison La Strada Top THC-Dominant Flower, #8 Lola Montes Top Balanced Oil, #3 Edison 5:5
16
Biosynthetic Cluster A physically clustered group of two or more genes in a particular genome that together encode a biosynthetic pathway for the production of a specialized metabolite.
i
INSERT BIOSYNTHETIC CLUSTER INTO DNA VECTOR The process is conducted at a large scale, resulting in materials that can be further processed into purified cannabinoids GENOME ENGINEERING OF HOST DNA is inserted into the bacteria, where it provides instructions to produce cannabinoid compounds(s).
How it works?
Biosynthesis can be used to produce cannabinoids that are biologically identical to those produced by the plant itself.
BIOSYNTHESIS
A proprietary cannabinoid manufacturing system that can product rare cannabinoids.
naturally produce cannabinoids without growing cannabis plants
cannabinoids at a fraction of the cost of traditional cultivation
metabolism causing the production of cannabinoid precursors by the yeast
the production of CBG, CBD and THC from the precursor molecules
17
Pre-rolls 7% & other
most established medical cannabis producers, Canndoc Ltd., a sub of InterCure Ltd. (TASE: INCR/INCR.TA) and a pioneer in pharmaceutical-grade cannabis for > 12 years
cultivation and distribution agreements in the EU and Canada
Israeli medical market
additional 3,000kg during the same time period subject to certain conditions
in the Israeli and EU markets, and grants exclusivity and related rights to Canndoc within the Israel market for a period of approximately 7.5 years
from Health Canada, the Israeli Ministry of Health, and any other applicable regulatory authorities.
18
Pre-rolls 7% & other
for Phases 4 and 5 of the Moncton Campus Facility
investment (GIC)
weighted average price of $2.21 per common share and net proceeds of $29.8M
weighted average price of $2.54 per common share
19
Julie Chamberlain Paolo DeLuca Tim Emberg Helen Martin Cameron Bishop Matt Rogers
VP, Marketing
professional known for her ability to translate market and consumer insights into strategic brand opportunities, relevant products, and powerful campaigns.
Group, most recently as General Manager, NYX Professional Makeup Canada and Vice President, Marketing for L'Oréal Paris USA.
Chief Strategy Officer
diversified financial business experience in senior financial, investor relations and accounting roles.
includes roles at West Face Capital, Meridian LNG, Potash Ridge, C.A. Bancorp and TD Securities. SVP, Sales
sales, marketing and market access and regulatory leader with proven experience in healthcare, over-the- counter and CPG
roles at Roche Canada, Jamieson Laboratories and Frito-Lay Canada.
Greg Engel
Chief Executive Officer
30 years of Canadian and international experience within the pharma, biotech, cannabis and CPG industries.
was most recently the CEO of Tilray.
SVP, Strategic & Legal Affairs
professional with experience spanning private practice corporate and securities law.
served for four years as the COO of a TSX-listed issuer within the financial sector.
VP, Public Affairs & Stakeholder Relations
with over 20 years of experience in government affairs and stakeholder relations.
led government affairs for Tilray and held various health policy and government relations roles outside
industry.
VP, Operations
first employees from 2015, Matt has held various operational roles within the company.
improvement,
and cost control experience from his prior roles at Ganong Bros., Canada’s oldest candy company.
Derrick West
Chief Financial Officer
the Audit Committee of OGI's Board from December 2017 to February 2020 and more recently served as part of the Investment Committee.
chartered accountant - served in various CFO and executive financial and accounting roles.
OGI INVESTORS’ PRESENTATION |
21
* not meaningful
($ IN 000S) UNLESS OTHERWISE INDICATED Q3 2020 Q3 2019 % CHANGE
Gross revenue 22,241 30,361
Excise taxes (4,220) (5,611)
Net revenue 18,021 24,750
Cost of sales 44,375 12,473 256% Gross margin before fair value changes to biological assets & inventories sold (26,354) 12,277
Fair value changes to biological assets & inventories (23,862) (12,456) 92% Gross margin (50,216) (179) nm* Sales & marketing and general & administrative expenses (“SG&A”)1 10,258 9,063 13% Net loss (89,323) (10,180) 777% Adjusted EBITDA2 (24,739) 7,712
Net cash provided by operating activities 8,527 3,006 184%
22
($ IN 000S UNLESS OTHERWISE INDICATED) 31-MAY-20 31-AUG-19 % CHANGE
Cash & Short-Term Investments 44,777 47,935
Biological Assets & Inventories 100,634 113,796
Other Current Assets 17,226 34,550
A/P and Other Current Liabilities 31,015 43,864
Working Capital 131,622 152,417
Property, Plant & Equipment 249,719 218,470 14% Long-Term Debt 78,884 46,067 71% Total Assets 433,677 428,525 1% Total Liabilities 112,971 101,519 11% Shareholders’ Equity 320,706 327,006
23
(in 000s) unless indicated FISCAL 2019 FISCAL 2018 % CHANGE Gross revenue 97,547 12,429 685% Excise taxes (17,134)
Net revenue 80,413 12,429 547% Cost of sales (incl. indirect production) 42,521 6,814 524% Gross margin (GM) before FV changes 37,892 5,615 575% FV changes to bio assets & inventories 10,577 46,018 (77)% Gross margin 48,469 51,633 (6)% SG&A1 33,218 10,989 202% Net income (loss) from continuing ops (9,504) 22, 124 n/m Select Non-IFRS Metrics GM before FV changes as % of net revenue 47% 45% 2% SG&A as a % of net revenue 41% 88% (47)% Adjusted EBITDA2 19,900 (1,003) n/m Adjusted EBITDA as a % of net revenue2 25% n/m n/m
24
(in 000s) FISCAL 2019 FISCAL 2018 % CHANGE Cash & Short-Term Investments 47,935 130,064 (63%) Biological Assets & Inventories 113,796 64,827 76% Other Current Assets 34,550 8,323 315% Accounts Payable and Other Current Liabilities 43,864 11,250 290% Working Capital 152,417 191,964 (21)% Property, Plant & Equipment 218,470 98,639 122% Long-Term Debt 46,067 98,473 (53)% Total Assets 428,525 302,567 42% Total Liabilities 101,519 117,973 (14)% Shareholders’ Equity 327,006 184,594 77%